Protalix BioTherapeutics, Inc.
PLX · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.5% | 37.5% | 24.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 54.5% | 64.9% | 58.9% | 57.4% |
| EBITDA | $0 | $0 | -$0 | -$0 |
| % Margin | 12.2% | 19.8% | -22.6% | -49.4% |
| Net Income | $0 | $0 | -$0 | -$0 |
| % Margin | 5.5% | 12.7% | -31.3% | -71.9% |
| EPS Diluted | 0.037 | 0.1 | -0.31 | -0.62 |
| % Growth | -63.4% | 132.3% | 50% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |